



**PATENT** 

Docket No. 2026-4205

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Topalian, et al.

Group Art unit: 1645

Serial No.

08/533,895

Examiner: Caputa, A.

Filed

September 26, 1995

For

MHC CLASS II RESTRICTED MELANOMA ANTIGENS

AND THEIR USE IN THERAPEUTIC METHODS

## RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.115

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In response to the Official Action mailed April 29, 1998, applicants present the following amendments and remarks. Applicants have petitioned herewith and paid the fee for a three-month extension of time thereby extending the period for reply up to and including October 29, 1998.

## **IN THE CLAIMS**

Please cancel claims 3-30, 56 and 61.

11/02/1998 NMARHOL 00000051 D1533895 amend the claims as follows

02 FC:102

(amended)

An isolated MHC Class II immunogenic derivative of

tyrosinase, wherein said derivative [contains] comprises at least a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO:

1), NILLSNAPLGPQFP (Ty 57-70) (SEQ ID/NO: 2) DYSYLQDSDPDSFQD (Ty 448-462)

427941 1